Fresh cash infusions are on the way for European biotech after two leading venture capital firms announced large new funds. Asset-focused Medicxi has closed an oversubscribed €500 million (US$580 million) fund, while Sofinnova Partners exceeded its target of €500 million to close its Capital XI fund at €650 million (US$753.5 million).

While Europe’s biotech sector continues to face headwinds, med tech appears to be weathering the storm more effectively. Uncertainty in the U.S., heightened competition from China and a persistent lack of capital are all impacting the investment landscape, delegates heard at the LSX Investival Showcase in London.

Mitorx Therapeutics Ltd. has raised £5.5 million (US$7.2 million) in a pre-series A round to advance its lead mitochondrial-targeted program, Myo-004, through clinical candidate selection.

Cornerstone Robotics Ltd. raised an oversubscribed $200 million series D round to accelerate commercialization of its flagship product, the Sentire Endoscopic Surgical System.

A year ago, BioWorld published a special series on the women’s health drug development ecosystem, showing that while women make up half of the population, venture capital investment and life sciences partnerships in the space – specifically those deals supporting innovations for conditions primarily affecting women – pale in comparison to efforts addressing diseases more men experience. That appears to be changing, according to an updated look of BioWorld data, supported by findings in the Silicon Valley Bank 2025 Innovation in Women’s Health Report published in April, and Clarivate’s Nov. 13 release of its latest Companies to Watch 2025 report, Rediscovering women’s health.

Siemens AG will deconsolidate its remaining 67% stake in Siemens Healthineers AG to a significant minority as it looks to have greater flexibility in capital allocation. The company will transfer 30% of Siemens Healthineers shares to Siemens AG shareholders via a spin-off to unlock long-term value and allow both companies to fully realize their growth potential.